{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T21:40:53Z","timestamp":1782337253844,"version":"3.54.5"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100013362","name":"Swiss Cancer Research Foundation","doi-asserted-by":"publisher","award":["HSR-5223-11-2020"],"award-info":[{"award-number":["HSR-5223-11-2020"]}],"id":[{"id":"10.13039\/501100013362","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.jtct.2025.11.020","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T02:49:23Z","timestamp":1763347763000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Late toxicity of allogeneic stem cell transplantation for Non-Hodgkin lymphoma patients. SBST based analysis 1997-2021 and review of literature"],"prefix":"10.1016","author":[{"given":"A.","family":"von Werdt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3115-9156","authenticated-orcid":false,"given":"A.","family":"K\u00fcnzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Haynes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2672-431X","authenticated-orcid":false,"given":"D.","family":"Schneidawind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Wolfensberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7092-3351","authenticated-orcid":false,"given":"J.","family":"Passweg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5740-2035","authenticated-orcid":false,"given":"S.","family":"Morin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Baldomero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7716-3340","authenticated-orcid":false,"given":"A.","family":"Schnegg-Kaufmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9341-8104","authenticated-orcid":false,"given":"Y.","family":"Chalandon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7757-4753","authenticated-orcid":false,"given":"A.","family":"Rovo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9478-4069","authenticated-orcid":false,"given":"E.","family":"Rebmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2025.11.020_bib0001","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1200\/JCO.2010.32.8419","article-title":"Allogeneic transplantation for lymphoma","volume":"29","author":"Chakraverty","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2025.11.020_bib0002","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s11899-016-0319-0","article-title":"Allogeneic Stem Cell Transplantation for Non-Hodgkin Lymphoma","volume":"11","author":"Bhatt","year":"2016","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.jtct.2025.11.020_bib0003","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.jcyt.2024.05.002","article-title":"Allogeneic transplantation after immunotherapy for relapsed\/refractory non-Hodgkin lymphoma: a comparison with a historical cohort","volume":"26","author":"Mariotti","year":"2024","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jtct.2025.11.020_bib0004","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/bmt.2014.198","article-title":"Retrospective comparison of allogeneic vs autologous transplantation for diffuse large B-cell lymphoma with early relapse or primary induction failure","volume":"50","author":"Ghobadi","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2025.11.020_bib0005","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1200\/JCO.2013.49.2454","article-title":"Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality","volume":"32","author":"Fenske","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2025.11.020_bib0006","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1200\/JCO.2012.46.0188","article-title":"Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma","volume":"31","author":"Smith","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2025.11.020_bib0007","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.bbmt.2009.08.011","article-title":"A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR","volume":"16","author":"Lazarus","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2025.11.020_bib0008","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.hoc.2019.03.005","article-title":"Allogeneic Stem Cell Transplantation and Chimeric Antigen Receptor (CAR) T-Cell Therapy for the Treatment of Non-Hodgkin Lymphoma","volume":"33","author":"Hunter","year":"2019","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.jtct.2025.11.020_bib0009","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1200\/JCO.2017.72.6869","volume":"35","author":"Mart\u00ednez","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2025.11.020_bib0010","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1200\/JCO.2010.33.7212","article-title":"Long-term survival and late deaths after allogeneic hematopoietic cell transplantation","volume":"29","author":"Wingard","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2025.11.020_bib0011","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1056\/NEJM199907013410103","article-title":"Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry","volume":"341","author":"Soci\u00e9","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2025.11.020_bib0012","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1182\/blood-2005-01-0035","article-title":"Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study","volume":"105","author":"Bhatia","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2025.11.020_bib0013","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1200\/JCO.2009.25.6693","article-title":"Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation","volume":"28","author":"Martin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2025.11.020_bib0014","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.hemonc.2017.05.009","article-title":"Long-term complications after hematopoietic cell transplantation","volume":"10","author":"Majhail","year":"2017","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"10.1016\/j.jtct.2025.11.020_bib0015","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3324\/haematol.2016.150250","article-title":"Late effects of blood and marrow transplantation","volume":"102","author":"Inamoto","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2025.11.020_bib0016","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.bbmt.2013.07.020","article-title":"Prevalence of hematopoietic cell transplant survivors in the United States","volume":"19","author":"Majhail","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2025.11.020_bib0017","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s12185-011-0811-1","article-title":"Mortality and medical morbidity beyond 2 years after allogeneic hematopoietic stem cell transplantation: experience at a single institution","volume":"93","author":"Munakata","year":"2011","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtct.2025.11.020_bib0018","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.3324\/haematol.2018.205211","article-title":"Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis","volume":"104","author":"Robin","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2025.11.020_bib0019","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1586\/ehm.09.48","article-title":"Late complications after hematopoietic stem cell transplantation","volume":"2","author":"Tichelli","year":"2009","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.jtct.2025.11.020_bib0020","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1182\/asheducation-2008.1.125","article-title":"Late pulmonary, cardiovascular, and renal complications after hematopoietic stem cell transplantation and recommended screening practices","author":"Tichelli","year":"2008","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jtct.2025.11.020_bib0021","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1182\/blood-2010-10-263095","article-title":"How I treat late effects in adults after allogeneic stem cell transplantation","volume":"117","author":"Savani","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2025.11.020_bib0022","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1002\/1097-0142(19910601)67:11<2795::AID-CNCR2820671114>3.0.CO;2-D","article-title":"Late renal dysfunction in adult survivors of bone marrow transplantation","volume":"67","author":"Lawton","year":"1991","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2025.11.020_bib0023","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1186\/s12882-020-02045-8","article-title":"Independent risk factors and long-term outcomes for acute kidney injury in pediatric patients undergoing hematopoietic stem cell transplantation: a retrospective cohort study","volume":"21","author":"Hirano","year":"2020","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.jtct.2025.11.020_bib0024","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/cncr.28444","article-title":"Cardiovascular disease in survivors of hematopoietic cell transplantation","volume":"120","author":"Armenian","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2025.11.020_bib0025","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.bbmt.2017.01.006","article-title":"Cardiovascular Function in Long-Term Hematopoietic Cell Transplantation Survivors","volume":"23","author":"Armenian","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2025.11.020_bib0026","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.926064","article-title":"Rapid cardiovascular aging following allogeneic hematopoietic cell transplantation for hematological malignancy","volume":"9","author":"Dillon","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jtct.2025.11.020_bib0027","doi-asserted-by":"crossref","first-page":"21","DOI":"10.7326\/0003-4819-155-1-201107050-00004","article-title":"Cardiovascular hospitalizations and mortality among recipients of hematopoietic stem cell transplantation","volume":"155","author":"Chow","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtct.2025.11.020_bib0028","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study","volume":"76","author":"Roth","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jtct.2025.11.020_bib0029","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1182\/bloodadvances.2019001126","article-title":"Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia","volume":"4","author":"Lee","year":"2020","journal-title":"Blood Advances"},{"key":"10.1016\/j.jtct.2025.11.020_bib0030","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1064146","article-title":"Thyroid function disorders and secondary cancer following haematopoietic stem cell transplantation in pediatrics: State of the art and practical recommendations for a risk-based follow-up","volume":"13","author":"Cattoni","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jtct.2025.11.020_bib0031","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.bbmt.2008.11.032","article-title":"Prolonged chronic graft-versus-host disease is a risk factor for thyroid failure in long-term survivors after matched sibling donor stem cell transplantation for hematologic malignancies","volume":"15","author":"Savani","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2025.11.020_bib0032","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1182\/blood-2011-10-384750","article-title":"Predicting posttransplantation diabetes mellitus by regulatory T-cell phenotype: implications for metabolic intervention to modulate alloreactivity","volume":"119","author":"Engelhardt","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2025.11.020_bib0033","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/sj.bmt.1705918","article-title":"High prevalence of early-onset osteopenia\/osteoporosis after allogeneic stem cell transplantation and improvement after bisphosphonate therapy","volume":"41","author":"Yao","year":"2008","journal-title":"Bone Marrow Transplantation"},{"key":"10.1016\/j.jtct.2025.11.020_bib0034","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.bbmt.2007.01.085","article-title":"Increased risk of bone loss without fracture risk in long-term survivors after allogeneic stem cell transplantation","volume":"13","author":"Savani","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2025.11.020_bib0035","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S1083-8791(00)70039-5","article-title":"Mechanisms of osteoporosis after hematopoietic cell transplantation","volume":"6","author":"Weilbaecher","year":"2000","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2025.11.020_bib0036","doi-asserted-by":"crossref","first-page":"5400","DOI":"10.1182\/bloodadvances.2024012879","article-title":"Targeting CDC42 reduces skeletal degeneration after hematopoietic stem cell transplantation","volume":"8","author":"Landspersky","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2025.11.020_bib0037","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1007\/s00432-020-03500-7","article-title":"Secondary esophageal squamous cell carcinoma after hematopoietic stem cell transplantation","volume":"147","author":"Nomura","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.jtct.2025.11.020_bib0038","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1056\/NEJM199703273361301","article-title":"Solid Cancers after Bone Marrow Transplantation","volume":"336","author":"Curtis","year":"1997","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.jtct.2025.11.020_bib0039","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/sj.bmt.1702148","article-title":"Melphalan\/TBI is not more carcinogenic than cyclophosphamide\/TBI for transplant conditioning: follow-up of 725 patients from a single centre over a period of 26 years","volume":"25","author":"Kulkarni","year":"2000","journal-title":"Bone Marrow Transplantation"},{"key":"10.1016\/j.jtct.2025.11.020_bib0040","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1182\/blood-2007-07-099283","article-title":"Increased risk of breast cancer among survivors of allogeneic hematopoietic cell transplantation: a report from the FHCRC and the EBMT-Late Effect Working Party","volume":"111","author":"Friedman","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2025.11.020_bib0041","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1182\/blood-2008-05-158782","article-title":"Solid cancers after allogeneic hematopoietic cell transplantation","volume":"113","author":"Rizzo","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2025.11.020_bib0042","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/phar.2443","article-title":"Long-term Follow-up of Hematopoietic Stem Cell Transplant Survivors: A Focus on Screening, Monitoring, and Therapeutics","volume":"40","author":"Saunders","year":"2020","journal-title":"Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"},{"key":"10.1016\/j.jtct.2025.11.020_bib0043","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1200\/JCO.2001.19.2.464","article-title":"Solid Cancers After Bone Marrow Transplantation","volume":"19","author":"Bhatia","year":"2001","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.jtct.2025.11.020_bib0044","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1111\/ijd.17371","article-title":"Skin cancer risk after hematopoietic stem cell transplantation: a systematic review and meta-analysis","volume":"63","author":"Mansilla-Polo","year":"2024","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jtct.2025.11.020_bib0045","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.21037\/jgo-22-700","article-title":"Outcomes of patients with esophageal cancer after allogeneic hematopoietic stem cell transplantation","volume":"13","author":"Vasudevan Nampoothiri","year":"2022","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.jtct.2025.11.020_bib0046","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1038\/bcj.2011.14","article-title":"Long-term complications and side effects after allogeneic hematopoietic stem cell transplantation: an update","volume":"1","author":"Mohty","year":"2011","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jtct.2025.11.020_bib0047","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s11764-020-00976-7","article-title":"Late effects in survivors treated for lymphoma as adolescents and young adults: a population-based analysis","volume":"15","author":"Lo","year":"2021","journal-title":"J Cancer Surviv"},{"key":"10.1016\/j.jtct.2025.11.020_bib0048","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2023.10.010","article-title":"Severity of Chronic Graft-versus-Host Disease and Late Effects Following Allogeneic Hematopoietic Cell Transplantation for Adults with Hematologic Malignancy","volume":"30","author":"Lee","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2025.11.020_bib0049","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1007\/s00277-019-03714-x","article-title":"Risk factors predicting graft-versus-host disease and relapse-free survival after allogeneic hematopoietic stem cell transplantation in relapsed or refractory non-Hodgkin's lymphoma","volume":"98","author":"Jeon","year":"2019","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2025.11.020_bib0050","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41408-019-0261-1","article-title":"Allogeneic transplantation in elderly patients\u226565 years with non-Hodgkin lymphoma: a time-trendanalysis","volume":"9","author":"Shah","year":"2019","journal-title":"Blood Cancer Journal"},{"key":"10.1016\/j.jtct.2025.11.020_bib0051","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.bbmt.2014.10.021","article-title":"Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research","volume":"21","author":"Arai","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2025.11.020_bib0052","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1182\/blood-2015-04-639831","article-title":"Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia","volume":"126","author":"Ciurea","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2025.11.020_bib0053","first-page":"832","article-title":"Immune reconstitution after autologous hematopoietic stem cell transplantation in relation to underlying disease, type of high-dose therapy and infectious complications","volume":"85","author":"Steingrimsdottir","year":"2000","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2025.11.020_bib0054","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.imbio.2014.03.012","article-title":"Evolution of peripheral blood T lymphocyte subsets after allogenic or autologous hematopoietic stem cell transplantation","volume":"219","author":"Puissant-Lubrano","year":"2014","journal-title":"Immunobiology"},{"key":"10.1016\/j.jtct.2025.11.020_bib0055","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.beha.2006.06.007","article-title":"Reduced intensity conditioning (RIC) haematopoietic cell transplants in elderly patients with AML","volume":"19","author":"Niederwieser","year":"2006","journal-title":"Best Practice & Research Clinical Haematology"},{"key":"10.1016\/j.jtct.2025.11.020_bib0056","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1038\/sj.bmt.1702392","article-title":"Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma","volume":"25","author":"Nagler","year":"2000","journal-title":"Bone Marrow Transplantation"},{"key":"10.1016\/j.jtct.2025.11.020_bib0057","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2025.09.015","article-title":"Validation of Cure Assumptions when Analyzing ZUMA-7 Follow-up Data of Axicabtagene Ciloleucel and Standard of Care Therapy in Second-Line Relapsed\/Refractory Large B-cell Lymphoma","author":"Perales","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2025.11.020_bib0058","article-title":"ZUMA-23: A global, phase 3, randomized controlled study of axicabtagene ciloleucel versus standard of care as first-line therapy in patients with high-risk large B-cell lymphoma","volume":"41","author":"Westin","year":"2023","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.jtct.2025.11.020_bib0059","series-title":"The EBMT Handbook: Hematopoietic Cell Transplantation and Cellular Therapies","first-page":"189","article-title":"Short- and Long-Term Controls After HCT","author":"Su\u00e1rez-Lled\u00f3","year":"2024"},{"key":"10.1016\/j.jtct.2025.11.020_bib0060","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s11899-023-00694-8","article-title":"Managing Survivorship after Hematopoietic Cell Transplantation","volume":"18","author":"Khera","year":"2023","journal-title":"Curr Hematol Malig Rep"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725015957?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725015957?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T11:08:30Z","timestamp":1776856110000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636725015957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":60,"alternative-id":["S2666636725015957"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2025.11.020","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Late toxicity of allogeneic stem cell transplantation for Non-Hodgkin lymphoma patients. SBST based analysis 1997-2021 and review of literature","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2025.11.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}